PALB2

New Releases

Premium

Myriad Genetics' Panexia Predictive Pancreatic Cancer Test

The company is planning to develop a new diagnostic test for early detection of pancreatic cancer by combining PALB2 gene mutations with mutations in the BRCA 2 gene and p16 genes, to which Myriad also holds exclusive rights under 10 issued US patents. The test is slated for launch in 2010.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.